STAB News and Press, Statera Biopharma Inc. From 12/29/21

Statera Biopharma (NASDAQ:STAB) soars 10.2% premarket after submitting its Phase 3 clinical trial protocol for STAT-201 in the treatment of pediatric Crohn’s Disease (CD) to the FDA. The Phase 3 trial will evaluate the safety and efficacy of STAT-201 compared to placebo ...

FORT COLLINS, Colo., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to the U.S. Food and Drug Administrat...

Initial Study to Evaluate P harmacokinetics, Biomarkers and Safety of STAT-205 Targeting Preliminary Data 2022 FORT COLLINS, Colo., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB), a leading biopharmaceutical company creating next-genera...

Gainers: Siyata Mobile (NASDAQ:SYTA) +126%. Ensysce Biosciences (NASDAQ:ENSC) +94%. Trupanion (NASDAQ:TRUP) +35%. TESSCO Technologies (NASDAQ:TESS) +31%. Jumia (NYSE:JMIA) +25%. Novavax (NASDAQ:NVAX) +24%. Elevation Oncology (NASDAQ:ELEV) +22%. Statera Biopharma (NASDAQ:ST...

Statera Biopharma (NASDAQ:STAB) perks up 7.8% premarket following an announcement that the FDA has lifted the clinical hold placed on its Entolimod research and development activity in acute radiation syndrome (ARS). Based on the Company’s response, the FDA acknowle...

FORT COLLINS, Colo., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc . (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the U.S. Food and Drug Administration (FDA...

Statera Biopharma Inc. (STAB) Q3 2021 Earnings Conference Call November 15, 2021 5:30 PM ET Company Participants Nichol Ochsner – Executive Vice President-Investor Relations Michael K. Handley – President and Chief Executive Officer Peter Aronstam – Chief Financial Office...

Statera BioPharma (NASDAQ:STAB): Q3 GAAP EPS of -$0.47. Revenue of $236.5M Press Release For further details see: Statera BioPharma reports Q3 results

FORT COLLINS, Co., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today reported important corporate events and financial results fo...

FORT COLLINS, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and...